Literature DB >> 25869465

MMP-9 in atrial remodeling in patients with atrial fibrillation.

J Lewkowicz1, M Knapp2, A Tankiewicz-Kwedlo3, R Sawicki2, M Kamińska2, E Waszkiewicz2, W J Musiał2.   

Abstract

INTRODUCTION: Atrial fibrillation (AF) is the most common arrhythmia and is associated with significant morbidity and mortality. The impact of matrix metalloproteinases (MMPs) on structural atrial remodeling and sustainment of AF in patients with persistent and permanent AF is unresolved.
OBJECTIVES: The aim was to evaluate MMP-9 and its tissue inhibitor-1 (TIMP-1) as markers of atrial remodeling in patients with persistent AF (PAF) who underwent electrical cardioversion (ECV) and in patients with permanent AF (continuous AF, CAF). PATIENTS AND METHODS: Plasma levels of MMP-9 and TIMP-1, clinical findings, and echocardiographic parameters were evaluated in 39 patients with AF and in 14 controls with sinus rhythm.
RESULTS: The concentrations of MMP-9 were significantly higher in patients with PAF and CAF compared to controls. There was a significant increase of MMP-9 after ECV in the persistent AF group. The values of TIMP-1 were not significantly different between the groups. In patients with AF, MMP-9 levels were positively related to posterior wall thickness of the LV (r=0.356, P=0.049) and body mass index (r=0.367, P=0.046).
CONCLUSION: Elevated levels of MMP-9 were related to the occurrence and maintenance of AF. This suggests that MMP-9 can be a marker of atrial remodeling in patients with AF. Regulation of the extracellular collagen matrix might be a potential therapeutic target in AF.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Atrial remodeling; Fibrillation atriale; Inhibiteurs tissulaires des métalloprotéinases; Matrix metalloproteinases; Métalloprotéinases matricielles; Remodelage des oreillettes; Tissue inhibitors of metalloproteinases

Mesh:

Substances:

Year:  2015        PMID: 25869465     DOI: 10.1016/j.ancard.2014.12.004

Source DB:  PubMed          Journal:  Ann Cardiol Angeiol (Paris)        ISSN: 0003-3928


  4 in total

1.  Mechanisms of Quercetin against atrial fibrillation explored by network pharmacology combined with molecular docking and experimental validation.

Authors:  Xin Tan; Wei Xian; Xiaorong Li; Yongfeng Chen; Jiayi Geng; Qiyi Wang; Qin Gao; Bi Tang; Hongju Wang; Pinfang Kang
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

2.  The serum matrix metalloproteinase-9 level is an independent predictor of recurrence after ablation of persistent atrial fibrillation.

Authors:  Gang Wu; Shun Wang; Mian Cheng; Bin Peng; Jingjun Liang; He Huang; Xuejun Jiang; Lizhi Zhang; Bo Yang; Yongmei Cha; Hong Jiang; Congxin Huang
Journal:  Clinics (Sao Paulo)       Date:  2016-05       Impact factor: 2.365

3.  Serum Matrix Metalloproteinases and Left Atrial Remodeling-The Hoorn Study.

Authors:  Pauline B C Linssen; Hans-Peter Brunner-La Rocca; Casper G Schalkwijk; Joline W J Beulens; Petra J M Elders; Amber A van der Heijden; Roderick C Slieker; Coen D A Stehouwer; Ronald M A Henry
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

Review 4.  The Role of Oxidative Stress in Cardiovascular Aging and Cardiovascular Diseases.

Authors:  Carmine Izzo; Paolo Vitillo; Paola Di Pietro; Valeria Visco; Andrea Strianese; Nicola Virtuoso; Michele Ciccarelli; Gennaro Galasso; Albino Carrizzo; Carmine Vecchione
Journal:  Life (Basel)       Date:  2021-01-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.